Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Peptide containing doai
Reexamination Certificate
1999-12-17
2003-02-04
Tate, Christopher R. (Department: 1651)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Peptide containing doai
C514S002600, C530S316000, C435S068100
Reexamination Certificate
active
06514941
ABSTRACT:
TECHNICAL FIELD
The present invention relates, in general, to a casein hydrolysate, and, in particular, to a method of preparing a casein hydrolysate enriched in antihypertensive peptides, to the resulting hydrolysate and to a method of preventing or treating hypertension using same.
BACKGROUND
With the recent changes in eating habits, the incidence of adult diseases, including hypertension and hyperlipemia, is on the increase. There is also a mounting interest in preventive medicine and thus there is an intense search for substances that are both safe and prophylactically effective.
Animal models of diseases such as cerebral stroke (Yamori et al, Jpn. Circ. J. 38:1095 (1974)), myocardial infarction (Yamori et al, Atherosclerosis 42:15 (1982)) and arteriosclerosis have been developed. Using such models, it has been possible to demonstrate that proper nutrition can be an effective preventative even in animals having a genetic predisposition to circulatory diseases.
Experiments involving the use of animal models, namely spontaneously hypertensive rats (SHR) (Okamoto et al, Jpn. Circ. J. 27:282 (1963)) and stroke-prone SHR (SHRSP), have shown that excess intake of sodium chloride promotes high blood pressure, while certain nutrients protect against it. For example, it has been shown that when soybean protein, lysine, taurine, potassium, calcium, magnesium, palmitoleic acid, etc. are administered before the onset of hypertension, or at an early stage after onset and onwards, a prophylactic effect is obtained (Yamori et al, New horizon in preventing cardiovascular diseases, Yamori and Strasser eds., Elsevier, Amesterdam, pp. 1, (1989)).
It has become increasingly clear that substances derived from food proteins can play a variety of physiological roles. Certain of such substances have been shown to have blood cholesterol-lowering activity and antihypertensive activity (Karaki et al, Comp. Biochem. Physiol., 96C, 367, (1990)). Some are available commercially.
Recently, it has been reported that the angiotensin converting enzyme inhibitor (ACEI), captopril, inhibits the onset of stroke in the SHRSP at a dose that is not hypotensive (Ohta et al, Genetic. Hypertens. 218:393 (1992)). However, captopril has adverse side effects, such as inducing a skin rash. Administration of other substances known to be effective for circulatory diseases, particularly cerebral stroke, are also associated with adverse side effects, including induction of blood-pressure fluctuations and the like.
Therefore, from the standpoint of preventive medicine, there is a significant demand for dietary substances that are effective in preventing or delaying the onset of high blood pressure, particularly, cerebral stroke, and that are safe and relatively inexpensive. The present invention provides a method for producing such a substance.
SUMMARY OF THE INVENTION
The present invention relates to a method of preparing a casein hydrolysate that is enriched in the peptides C6, C7 and C12. The product of the present method can be used as a dietary preventative of circulatory diseases, more specifically, high blood pressure and associated diseases. Further, the present product is relatively free of adverse side effects associated with many antihypertensive pharmaceuticals.
Objects and advantages of the present invention will be clear from the description that follows.
REFERENCES:
patent: 4161520 (1979-07-01), Osborne et al.
patent: 4361564 (1982-11-01), Edwards
patent: 4816398 (1989-03-01), Brule et al.
patent: 5037957 (1991-08-01), Grubb et al.
patent: 5112812 (1992-05-01), Samuelsson et al.
patent: 5314873 (1994-05-01), Tomita et al.
patent: 5486461 (1996-01-01), Nielsen
patent: 5703212 (1997-12-01), Sugai et al.
patent: WO 95/28425 (1995-10-01), None
patent: WO 99/19354 (1999-04-01), None
patent: WO 99/31129 (1999-06-01), None
patent: WO 99/35246 (1999-07-01), None
Karaki, Antihypertensive effect of Tryptic Hydrolysate of Milk Casein in Spontaneously Hypertensive Rats, Comp. Biochem.Physiol.vol. 96C, No.2, pp. 367-371, Mar. 1990.*
JP05176714 — Abstract.
JP8269088 A 961015 — Abstract.
JP6128287 A 940510 — Abstract.
WO9102539 A — Abstract.
JP04169598 — Abstract.
JP9121855 — Abstract.
Madsen et al, “Hydrolysis of milk protein by aBacillus licheniformisprotease specific for acidic amino acid residues”, Journal of Food Science 62(3):579-582 (1997) — Abstract.
Park et al, “Identification of peptides derived from . . . proteolytic enzymes”, Korean Journal of Dairy Science 18(4):237-246 (1996) — Abstract.
Queiroz Macedo et al, “Caseinolytic specificity of cardosin, an aspartic protease from the cardoonCynara cardunculus L.: action on bovine ALPHAs-and BETA-casein and comparison with chymosin”, Journal of Agricultural and Food Chemistry 44(1):42-47 (1996) — Abstract.
Beeby, R., “The proteolysis of casein by immobilized preparations of ALPHA-chymotrypsin, chymosin and a fungal protease”, Dairy Res. Lab, CSIRO Div. of Food Res., Highett, New Zealand Journal of Dairy Science and Technology 14(1):1-11 (1979) — Abstract.
Braun Steven D.
Nimmagudda Ram
Primmer Michael
Tolton, II J. Kelly
van der Veerdonk Frans
Campina Melkunie B.V.
Nixon & Vanderhye P.C.
Tate Christopher R.
Winston Randall
LandOfFree
Method of preparing a casein hydrolysate enriched in... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Method of preparing a casein hydrolysate enriched in..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Method of preparing a casein hydrolysate enriched in... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3149711